中国肺癌杂志2025，Vol.28Issue(6)：477-481,5.DOI:10.3779/j.issn.1009-3419.2025.102.19
伏美替尼敏感的EGFR 20号外显子H773_V774delinsLM突变肺腺癌1例
Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation Sensitive to Furmonertinib:A Case Report
摘要
Abstract
Epidermal growth factor receptor(EGFR)exon 20 mutations represent a rare subset of genetic altera-tions in non-small cell lung cancer(NSCLC).Among them,the complex mutation H773_V774delinsLM is exceedingly un-common,accounting for only 0.2％-1％of all EGFR mutations.It is currently believed that rare EGFR mutations are generally resistant to the first-and second-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs).Although the third-generation EGFR-TKIs have shown some efficacy in certain rare mutations,clinical evidence regarding their use in NSCLC patients with the H773_V774delinsLM mutation remains sparse,and their efficacy and safety are yet to be clarified.Here,we present the first documented case of a patient with EGFR H773_V774delinsLM-mutant lung adenocarcinoma who experienced remark-able tumor regression following treatment with furmonertinib.This case highlights the potential utility of furmonertinib in treating patients with this rare EGFR mutation and may provide valuable insight into emerging treatment strategies for similarly affected patients.关键词
肺肿瘤/EGFR突变/罕见突变/伏美替尼Key words
Lung neoplasms/EGFR mutations/Rare mutations/Furmonertinib引用本文复制引用
李蓉真,徐燕,高晓星,陈闽江,钟巍,王孟昭..伏美替尼敏感的EGFR 20号外显子H773_V774delinsLM突变肺腺癌1例[J].中国肺癌杂志,2025,28(6):477-481,5.基金项目
This paper was supported by the grants from National High Level Hospital Clinical Research Funding(No.2022-PUMCH-B-106,to Mengzhao WANG （）
No.2022-PUMCH-C-054,to Wei ZHONG). 本文受中央高水平医院临床科研业务费(No.2022-PUMCH-B-106和No.2022-PUMCH-C-054)资助 （No.2022-PUMCH-B-106和No.2022-PUMCH-C-054）
